Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
| Autor: | Molina, Jean-Michel a, Rizzardini, Giuliano b, c, Orrell, Catherine d, e, Afani, Alejandro f, Calmy, Alexandra g, Oka, Shinichi h, Hinestrosa, Federico i, Kumar, Princy j, Tebas, Pablo k, Walmsley, Sharon l, Grandhi, Anjana m, Klopfer, Stephanie m, Gendrano, Isaias m, Eves, Karen m, Correll, Todd A m, Fox, Michelle C m, Kim, Jason m, * |
|---|---|
| Zdroj: | In The Lancet HIV June 2024 11(6):e369-e379 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|